Previous close | 40.30 |
Open | 41.00 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 180.00 |
Expiry date | 2025-01-17 |
Day's range | 40.30 - 41.00 |
Contract range | N/A |
Volume | |
Open interest | 87 |
Eleven people suffered bouts of dangerously low blood sugar in Lebanon this year, one of whom required hospitalization, after injecting suspected fake versions of Novo Nordisk's diabetes drug Ozempic, according Lebanese health officials. A director for the Lebanese Ministry of Public Health, Rita Karam, said officials suspected the drugs were fake after discovering the doses were different from the ones calibrated for authentic Ozempic injector pens.
Eleven people suffered bouts of dangerously low blood sugar in Lebanon this year, one of whom required hospitalization, after injecting suspected fake versions of Novo Nordisk's diabetes drug Ozempic, according Lebanese health officials. A director for the Lebanese Ministry of Public Health, Rita Karam, said officials suspected the drugs were fake after discovering the doses were different from the ones calibrated for authentic Ozempic injector pens. Explosive demand for Ozempic and other drugs used for weight loss, including Eli Lilly's Mounjaro and Novo's Wegovy, is fueling a global surge in counterfeit versions, Reuters interviews with law enforcement, anti-counterfeiting and public health officials showed last month.
The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.